VolitionRx Limited VNRX
Set alert
0.22 USD +0.02 +11.16%
As of Nov 2, 1:18 PM ET
0.195 Day range 0.22
0.16 52-week range 9.60
- YTD
- -95.82%
- 1 year
- -97.48%
- Open
- 0.2001
- Prev close
- 0.1953
- Mkt cap
- 6.53M
- Vol
- 980.46K
- Avg vol
- 8.70M
- EPS
- -3.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.195
- High
- 0.22
- Forward P/E
- -3.83
- Beta
- 1.10
- Short ratio
- 3.71
- Inst. own
- 19.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6652
- 200-d avg
- 0.6969
- 1y target
- 3.34
Key statistics
- Market cap
- 58.84M
- Enterprise value
- 61.40M
- Trailing P/E
- 0.00
- Forward P/E
- -3.83
- PEG ratio
- 0.00
- Price / sales
- 60.25
- Price / book
- 0.00
- EPS (TTM)
- -0.36
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 976.52K
- Revenue growth
- 83.00%
- Free cash flow
- -5.70M
- Total cash
- 6.00M
- Total debt
- 5.86M
- Return on equity
- 0.00%
- Shares outstanding
- 95.97M
- Short % of float
- 0.61%
- 50-day average
- 0.6652
- 200-day average
- 0.6969
Analyst view
Consensus: buy
Buy
Price target (mean) 3.34 +1438.5% upside
Now 0.2171
- Target (low)
- 2.00
- Target (mean)
- 3.34
- Target (high)
- 5.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.05.
Financials — quick view
VNRX Revenue — quarterly 398.66K
VNRX Net income — quarterly -7.33M
VNRX EPS — quarterly -0.85
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.07 | -0.07 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.09 | -0.08 | +0.01 | +11.11% |
| May 13, 2024 | Mar 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Mar 25, 2024 | Dec 1, 2023 | 0.00 | -0.11 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.12 | -0.11 | +0.01 | +8.33% |
| Aug 14, 2023 | Jun 1, 2023 | -0.13 | -0.14 | -0.01 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 22, 2024 | Benchmark | reit | — | Hold |
| Nov 15, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 1, 2024 | EF Hutton | main | Buy | Buy |
| Aug 16, 2024 | Benchmark | reit | — | Hold |
| Jun 7, 2024 | EF Hutton | main | Buy | Buy |
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- volition.com
News
- VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis
- VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
- VolitionRx Makes $500K Cash Partial Prepayment Towards Outstanding Principal Balance On Its Senior Secured Convertible Promissory Note
- VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
- VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average – What’s Next?
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
- VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding
- VolitionRx Participates in Launch of DETECSEPS Program in France
- VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025
- VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Your note
Sign in to keep a note on VNRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BUTERA SALVATORE THOMAS | Officer | Stock Award(Grant) | Nov 28, 2024 | 392,940 |
| COLMAN ALAN | Director | Stock Award(Grant) | Nov 28, 2024 | 230,524 |
| FORTERRE GAEL | Officer | Stock Award(Grant) | Nov 28, 2024 | 194,681 |
| HUGHES TERIG | Chief Financial Officer | Stock Award(Grant) | Nov 28, 2024 | 376,252 |
| INNES GUY ARCHIBALD | Director | Purchase | Dec 8, 2024 | 2,991,100 |
| KWAY JASMINE | Officer | Stock Award(Grant) | Nov 28, 2024 | 176,472 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.71% | 8,998,727 | 5.52M | Sep 29, 2024 |
| Lagoda Investment Management, L.P. | 6.58% | 6,095,000 | 3.74M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.79% | 730,448 | 447.84K | Sep 29, 2024 |
| Vanguard Group Inc | 0.69% | 636,667 | 390.34K | Sep 29, 2024 |
| Blackrock Inc. | 0.48% | 445,187 | 272.94K | Sep 29, 2024 |
| Silverberg Bernstein Capital Management LLC | 0.15% | 142,618 | 87.44K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.67% | 622,949 | 381.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 409,150 | 250.85K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 142,506 | 87.37K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 96,676 | 59.27K | Oct 30, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.02% | 15,384 | 9.43K | Jul 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.02% | 18,080 | 11.08K | Sep 29, 2024 |